SINGAPORE, Feb. 24, 2026 (GLOBE NEWSWIRE) -- RF Acquisition Corp III (the “Company” or “we”) announced that, commencing February 26, 2026, holders of the 10,000,000 units sold in the Company's initial public offering may elect to separately trade the ordinary shares and rights included in the units. Any units not separated will continue to trade on the Global Market tier of The Nasdaq Stock Market LLC (“Nasdaq”) under the symbol “RFAMU,” and the separated ordinary shares and rights are expected to trade on ...

Biotech is quietly stepping into a leadership role here in early 2026 — and the move is not happening in a vacuum.After years of underperformance from 2021 through much of 2024, the sector began a powerful rebound in the second half of 2025.  That rally was significant. From its April 2025 lows, the SPDR S&P Biotech ETF (NASDAQ: IBB) surged roughly 75%, dramatically outperforming the broader market’s move over the same period.In many ways, that outperformance looked like a long-overdue catch-up trade.  ...

Core Insights - The article discusses the background and achievements of Brendan, highlighting his academic and professional journey in the pharmaceutical and biotechnology sectors. Group 1: Academic Background - Brendan completed a Ph.D. at Stanford University in organic synthesis in 2009 [1] Group 2: Professional Experience - He worked for Merck, a major pharmaceutical company, from 2009 to 2013 [1] - Brendan has experience in biotech, including startups such as Theravance and Aspira, before joining Caltech [1] - He was the first employee and co-founder of 1200 Pharma, which spun out of Caltech and secured significant investment in the eight figures [1] Group 3: Investment Focus - Brendan remains an avid investor, concentrating on market trends, particularly in biotechnology stocks [1]

Scanlon argued that biotechnology and biofermentation are increasingly central to solving industry challenges, citing pressures such as climate volatility, finite raw materials, and consumer demands for simpler labels, better nutrition, functional benefits, and authentic taste at a competitive cost. He said biotechnology enables scalable solutions that are not limited by traditional agriculture and can support cleaner labels, improved nutrition, consistent taste, and reduced environmental impact.Scanlon hig ...

Summary of Kerry's Conference Call Company Overview - **Company**: Kerry Group - **Industry**: B2B Specialty Ingredients for Food and Beverage - **Revenue**: EUR 7 billion - **Global Presence**: 119 manufacturing facilities across 34 countries, reaching nearly 1.5 billion consumers globally [4][6] Core Points and Arguments Strategic Focus - Kerry aims to deliver high single-digit earnings growth through consistent volume growth and margin expansion [3][6] - The company has transformed into a pure-play taste and nutrition company under CEO Edmond Scanlon, leading to significant margin expansion [1][4] Financial Performance - Revenue growth from EUR 4 billion in 2017 to EUR 7 billion today, with a target of high single-digit earnings compounding [6] - Achieved double-digit adjusted earnings per share growth on average since 1986, with high single-digit growth in 8 of the last 10 years [6] - EBITDA margin expanded by over 300 basis points in the past four years, targeting 19%-20% by 2028 [7][49] Market Dynamics - The food and beverage market is dynamic, with over 70% of global consumers reporting changes in preferences over the last three years [22][23] - High protein products are growing at over 7% CAGR, while non-protein products remain in low single digits [24] - Over 60% of new food and beverage activity involves reformulation, driven by cost reduction and clean label demands [13][14] Innovation and Renovation - Kerry is positioned at the intersection of innovation and renovation, helping customers create new products while transforming existing ones [14] - Significant investments in biotechnology, with over EUR 3 billion in science and technology over the last decade [5][11] - Recent innovations include fermentation-derived technologies for taste and health benefits, such as sweet and salt reduction technologies [12] Regional Performance - **Americas**: Consistent volume growth of 3%-4%, with strong market outperformance due to customer access and tailored go-to-market strategies [16] - **APMEA**: Revenues over EUR 1.6 billion, with significant growth in Southeast Asia and the Middle East, focusing on local culture and authentic flavors [18] Regulatory Landscape - Global front-of-pack nutritional labeling regulations are expanding, creating opportunities for Kerry in product reformulation [20] Additional Important Content - Kerry's Accelerate 2.0 program aims to drive operational excellence and margin expansion, with a target of EUR 100 million in annual benefits by 2028 [42][45] - The company maintains a balanced capital allocation strategy, investing 4%-5% of revenues in growth while returning capital to shareholders through dividends and share buybacks [46][48] - Sustainability efforts include a 52% reduction in carbon emissions and a 54% reduction in food waste [39] Conclusion - Kerry is well-positioned to capitalize on market dynamics through innovation and renovation, with a strong focus on biotechnology and customer partnerships, aiming for continued earnings growth and market outperformance [50]

SINGAPORE, Feb. 18, 2026 (GLOBE NEWSWIRE) -- RF Acquisition Corp III (the “Company”) today announced that it closed its initial public offering of up to 10,000,000 units at a price of $10.00 per unit on February 17, 2026. The units are listed on the Nasdaq Global Market (“Nasdaq”) and began trading under the ticker symbol “RFAMU” on February 13, 2026. Each unit consists of one ordinary share, par value $0.0001 per share, of the Company (“ordinary share”), and one right to receive one-tenth of one ordinary s ...

Last year , I initiated Madrigal Pharmaceuticals, Inc. ( MDGL ) as a Strong Buy due to the blockbuster pace of commercialization for Rezdiffra following FDA approval in March 2024. Since then, the stock has appreciated from $293 to $465, a robust gain of 58% outpacingBrendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior ...

Lilly to participate in TD Cowen's 46th Annual Health Care Conference [Accessibility Statement] Skip NavigationINDIANAPOLIS, Feb. 16, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in TD Cowen's 46th Annual Health Care Conference on March 2, 2026. Lucas Montarce, executive vice president and chief financial officer, will take part in a fireside chat at 3:10 p.m., Eastern time.A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's investor website ...

Imagine [music] [music] [applause] your body as a living city, fast forward, vibrant, full of motion and in constant. In our body, billions of cells work together in perfect harmony, in perfect coordination, each with a purpose, each in its destiny. But sometimes that's harmony break.A single cell loses its way and begin to grow out of control. An illegal, dangerous building rises in the city. A tumor.Now imagine sending a tiny invisible robots ghost [snorts] that can find this building and destroy it from ...

Every future begins somewhere, and mine has a very strong, very strong connection to the environment, a very strong connection to the reality of the Amazon. Those who live in Pará will certainly know what I’m talking about when I talk about the rain. My parents, when they were young, when they started dating, unlike young people today who schedule dates via WhatsApp.That is, unless a personal meeting is replaced by a digital one. In their time, they would meet after the rain. This was the time for couples t ...